Dec 18, 2025 | Clinical Outcomes, News
Abstract Introduction Intravenous immune globulin 10% liquid (IVIG 10%) is used in the treatment of primary immunodeficiency (PID). Originally approved in 2012 and then voluntarily withdrawn in 2016, IVIG 10% (BIVIGAM®) underwent manufacturing process improvements by...
Dec 3, 2025 | Clinical Outcomes, News
Abstract Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment. Inclisiran, a novel RNA therapeutic agent, offers a promising solution...
Oct 25, 2025 | Clinical Outcomes
Presented at ACG 2025 The Healix Research Team is honored to be showcasing our latest collaborative clinical research with our esteemed physician partners and Ferring Pharmaceuticals at ACG2025 this weekend in Phoenix. If you’re participating in the meeting, we...
Oct 20, 2025 | Clinical Outcomes
Presented at IDWeek 2025 Authors: Richard L. Hengel, MD, FIDSA Brian Metzger, MD, MPH Erika M. Young, DO Kent J. Stock, DO Joseph F. John, Jr., MD, FACP, FIDSA Kimberly A. Couch, PharmD, MA, FIDSA Christina Weeks, PharmD Lucinda J. Van Anglen, BS, PharmD, FIDSA View...
Oct 19, 2025 | Clinical Outcomes
Presented at IDWeek 2025 Authors: Richard L. Hengel MD Sujatha Krishan, MD Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD, MS Kevin W....
Oct 19, 2025 | Clinical Outcomes
Presented at IDWeek 2025 Authors: Nikhil K. Bhayani, MD, FIDSA Jorge R. Bernett, MD Thomas K. Sleweon, MD Erika M. Young, DO Kent J. Stock, DO Stacey E. Baker, MD Quyen Luu, MD Brian S. Metzger, MD, MPH Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Christina J. Weeks,...
Recent Comments